The directors of Asarina Pharma have abandoned a search for a partner for Tourette's syndrome treatment sepranolone, saying they have no choice but to liquidate the company.
Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.